Biomarkers in individualized management of chimeric antigen receptor T cell therapy

The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission rates of CAR-T cell therapy in previously untreatable, refractory and/or rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Mengyi, Hari, Parameswaran, Hu, Yu, Mei, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216329/
https://www.ncbi.nlm.nih.gov/pubmed/32426136
http://dx.doi.org/10.1186/s40364-020-00190-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216329/
https://www.ncbi.nlm.nih.gov/pubmed/32426136
http://dx.doi.org/10.1186/s40364-020-00190-8

Ejemplares similares